Advertisement

Topics

GS no update yet - on sept 11 $RVNC RVNC: Our 12-month price target of $60 is based 70% on a DCF value of $57, which assumes an 11% WACC and 0% terminal growth rate, and 30% on an M&A value of $66 that uses a 6.5x EV multiple on 2025 sales (5 years post i

16:55 EDT 14 Sep 2018 | tgtxdough

GS no update yet - on sept 11 RVNC: Our 12-month price target of $60 is based 70% on a DCF value of $57, which assumes an 11% WACC and 0% terminal growth rate, and 30% on an M&A value of $66 that uses a 6.5x EV multiple on 2025 sales (5 years post initial launch of RT002).

Original Article: GS no update yet - on sept 11 $RVNC RVNC: Our 12-month price target of $60 is based 70% on a DCF value of $57, which assumes an 11% WACC and 0% terminal growth rate, and 30% on an M&A value of $66 that uses a 6.5x EV multiple on 2025 sales (5 years post i

NEXT ARTICLE

More From BioPortfolio on "GS no update yet - on sept 11 $RVNC RVNC: Our 12-month price target of $60 is based 70% on a DCF value of $57, which assumes an 11% WACC and 0% terminal growth rate, and 30% on an M&A value of $66 that uses a 6.5x EV multiple on 2025 sales (5 years post i"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...